Novel insights into metabolic-associated steatotic liver disease preclinical models

Liver Int. 2024 Mar;44(3):644-662. doi: 10.1111/liv.15830. Epub 2024 Jan 30.

Abstract

Metabolic-associated steatotic liver disease (MASLD) encompasses a wide spectrum of metabolic conditions associated with an excess of fat accumulation in the liver, ranging from simple hepatic steatosis to cirrhosis and hepatocellular carcinoma. Finding appropriate tools to study its development and progression is essential to address essential unmet therapeutic and staging needs. This review discusses advantages and shortcomings of different dietary, chemical and genetic factors that can be used to mimic this disease and its progression in mice from a hepatic and metabolic point of view. Also, this review will highlight some additional factors and considerations that could have a strong impact on the outcomes of our model to end up providing recommendations and a checklist to facilitate the selection of the appropriate MASLD preclinical model based on clinical aims.

Keywords: MASLD; animal models; liver fibrosis; steatohepatitis.

Publication types

  • Review

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular*
  • Fatty Liver*
  • Liver Cirrhosis
  • Liver Neoplasms*
  • Mice